Academy of Finland
Funding decision
Name Piltonen, Terhi
Organisation OYS
Project title
Antimüllerian hormone (AMH) –new player in the early onset pathogenesis of pregnancy complications and hormonal and metabolic derangements later in life.
Decision No. 315921
Decision date 30.05.2018
Funding period 01.09.2018 - 31.08.2022
Funding 292 166
WebFOCUS Report
Project description
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in fertile aged women (18%). It is thought to stem from prenatal androgen exposure together with genetic and environmental factors. 70% of PCOS women are obese with high risk for metabolic syndrome and diabetes. The women have also endometrial and placental dysfunction with increased risk for endometrial cancer, miscarriage, preeclampsia, gestational diabetes and preterm birth. Antimüllerian hormone (AMH) is secreted from the ovaries and the serum levels are 50% elevated in PCOS compared to other women. Recently, AMH was shown to induce pituitary LH pulsatility and hyperandrogenism promoting PCOS phenotype in mice. Our unpublished data shows that gestational AMH treatment can promote PCOS also in the female offspring. This study aims to reveal the role of AMH in PCOS pathogenesis and pregnancy complications in humans enabling studies targeting new preventing actions in the future.